Table 1. Sequencing and sorting metrics.

Patient	Tumor	Tissue	Sorted with	Ploidy	Mutations/Mb	Mean coverage	Total reads
P6	Primary	FF	DAPI	3.6	2.4	57.99	116,651,162
P6	Metastasis	FF	DAPI	3.4	6	69.02	160,142,677
P6	Non-tumor	FF	DAPI	2	–	62.17	137,946,635
P9	Primary	FF	DAPI	3.9	4.6	68.41	148,484,030
P9	Metastasis	FF	DAPI	4	6.2	73.91	150,098,988
P9	Non-tumor	FF	DAPI	2	–	62.55	132,798,619
P18	Primary	FF	DAPI	3.6	6.6	51.15	114,207,787
P18	Metastasis	FF	DAPI	3.3	6.6	73.17	127,941,373
P18	Non-tumor	FF	DAPI	2	–	77.15	152,991,220
P103	Primary	FFPE	DAPI/pCK	3.3	6.9	63.32	199,580,439
P103	Metastasis	FFPE	DAPI/pCK	3.2	6.1	75.91	177,816,752
P103	Non-tumor	FFPE	DAPI/pCK	2	–	32.34	127,962,411
P109	Primary	FF	DAPI	3.6	6.2	91.92	142,302,414
P109	Metastasis1	FFPE	DAPI/pCK	2	9.4	51.75	210,698,902
P109	Metastasis2	FFPE	DAPI/pCK	1.8	4.8	98.72	157,381,241
P109	Non-tumor	FFPE	DAPI/pCK	2	–	58.87	231,972,945

FF, fresh frozen; FFPE, formalin-fixed paraffin-embedded; DAPI, 4',6-diamino-2-phenylindole; pCK, pan-cytokeratin.